Department of Microbiology and Immunology, McGill University, 3775 University Street, Montreal, Quebec, H3A2B4, Canada.
Rajendra Memorial Research Institute of Medical Sciences (ICMR), Patna, Bihar, India.
BMC Infect Dis. 2018 Oct 3;18(1):500. doi: 10.1186/s12879-018-3420-2.
Visceral leishmaniasis (VL), caused by Leishmania donovani complex parasites, is a neglected parasitic disease that is generally fatal if untreated. Despite decades of research to develop a sensitive VL diagnostic test, definitive diagnosis of VL still mainly relies on the visualization of the parasite in aspirates from the spleen, liver or bone marrow, an invasive and dangerous process with variable sensitivity. A sensitive assay that can detect Leishmania antigen from blood samples will help confirm cause, cure or recurrence of VL.
In this study, rabbit polyclonal antibodies were raised against eight recombinant Leishmania proteins that are highly abundant in Leishmania. The antibodies were purified and labeled with biotin for developing a prototype sandwich enzyme-linked immunosorbent assay (ELISA).
The ELISA for the Leishmania 40S ribosomal protein S12 detected target antigen with the highest sensitivity and specificity and could detect 1 pg of purified protein or as few as 60 L. donovani parasites. The 40S ribosomal protein S12 sandwich ELISA could detect the target antigen from Peripheral Blood Mononuclear Cell (PBMC) samples in 68% of VL patients and post-kala-azar dermal leishmaniasis (PKDL) patients, providing an estimation of parasitemia ranging from 15 to 80 amastigotes per ml of blood.
These results indicate that the 40S ribosomal protein S12 sandwich ELISA warrants further tests with more clinical samples of VL patients and other parasitic diseases. It is hopeful that this ELISA could become a useful tool for confirming VL diagnosis, monitoring treatment progress, disease recurrence and possibly detecting asymptomatic Leishmania infections with a high parasite load.
内脏利什曼病(VL)由利什曼原虫复合体寄生虫引起,如果未经治疗,通常是致命的。尽管几十年来一直在研究开发一种敏感的 VL 诊断测试,但 VL 的明确诊断仍然主要依赖于从脾脏、肝脏或骨髓抽吸物中观察寄生虫,这是一种具有不同敏感性的侵入性和危险过程。一种能够从血液样本中检测利什曼抗原的敏感检测方法将有助于确认 VL 的病因、治愈或复发。
在这项研究中,针对在利什曼原虫中高度丰富的八种重组利什曼蛋白,制备了兔多克隆抗体。将抗体纯化并用生物素标记,用于开发原型夹心酶联免疫吸附试验(ELISA)。
用于检测 40S 核糖体蛋白 S12 的 ELISA 具有最高的灵敏度和特异性,能够检测到 1pg 纯化蛋白或低至 60 个利什曼原虫寄生虫。40S 核糖体蛋白 S12 夹心 ELISA 能够从 68%的 VL 患者和 post-kala-azar dermal leishmaniasis(PKDL)患者的外周血单核细胞(PBMC)样本中检测到靶抗原,估计血液中的寄生虫载量为每毫升 15 至 80 个无鞭毛体。
这些结果表明,40S 核糖体蛋白 S12 夹心 ELISA 值得进一步用更多 VL 患者和其他寄生虫病的临床样本进行测试。希望这种 ELISA 能够成为一种有用的工具,用于确认 VL 诊断、监测治疗进展、疾病复发,并可能检测出具有高寄生虫载量的无症状利什曼感染。